Trevarx Biomedical
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2929 Arch St Fl 3, Philadelphia, Pennsyl...Website
www.trevarx.comRevenue
<$5 MillionIndustry
About Trevarx Biomedical
Trevarx Biomedical Org Chart
Is Trevarx Biomedical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Trevarx Biomedical has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Trevarx Biomedical recently announced quarterly report
Funding: Get notified immidiatlly once Trevarx Biomedical has new funding data
Check out if Trevarx Biomedical is spiking on competitors!
Product Launch: Get notified when Trevarx Biomedical launches new products
Congratulate Masked Content for being promoted to Masked Content at Trevarx Biomedical
Trevarx Biomedical, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Trevarx Biomedical had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Trevarx Biomedical as Masked Content
Find 3 more new buyers
Trevarx Biomedical financials insights
Gather financial insights about Trevarx Biomedical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$350K
Trevarx Biomedical Tech Stack
A closer look at the technologies used by Trevarx Biomedical
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Trevarx Biomedical
Trevarx Biomedical is focused on developing innovative alpha-targeted radiopharmaceuticals that deliver targeted radioligand therapy directly to cancer DNA. Their approach aims to overcome the limitations of current therapies by targeting nuclear DNA to induce irreversible genomic damage. The company holds proprietary intellectual property covering... Read More